Genetic therapy for transplant vascular sclerosis.
Bennett
C F
CF
Isis Pharmaceuticals Inc., Carlsbad, CA 92009, USA.
Stepkowski
S M
SM
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000276:immunology / Q000628:therapy*; D015316:Genetic Therapy; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics / Q000494:pharmacology; D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D016377:Organ Transplantation / Q000009:adverse effects*; D054735:Phosphorothioate Oligonucleotides; D013873:Thionucleotides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D054735:Phosphorothioate Oligonucleotides; D013873:Thionucleotides; D018799:Intercellular Adhesion Molecule-1; C089753:alicaforsen